- $692.21m
- $460.10m
Brief: Immix Biopharma Informs It Holds No Cash Deposits Or Securities At Silvergate Bank Or Silicon Valley Bank
Brief: Immix Biopharma Confirms No Exposure To Silicon Valley Bank Or Silvergate Bank
Brief: Nexcella Announces 50 Patients Already Treated With Car-T Nxc-201 Estimates 100-Patient Total Enrollment For FDA Approval BLA Submission
Brief: Immix Biopharma Subsidiary Nexcella Enters Into U.S. Gmp Manufacturing Agreement To Expand Ongoing Nxc-201 Phase 1B/2 Clinical Trial To The U.S.
Brief: Immix Unit Presents Interim Data, With 90% Overall Response Rate In Relapsed Or Refractory Multiple Myeloma At NXC-201 Therapeutic Dose From Its Phase 1 Expansion Trial At The 5Th European Car T-Cell Meeting
Brief: Immix Biopharma Announces Dosing Of First Two Patients With Experimental Drug For Advanced Cancer
Brief: Immix Biopharma Doses Additional Patients In Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical Trial
Brief: Nexcella Announces Additional Positive NXC-201 Clinical Data
Brief: Immix Biopharma Files For Mixed Shelf Of Up To $250 Mln
Brief: Immix Biopharma Announces 16th Patient Dosing In Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical Trial
Brief: Immix Biopharma Announces 16th Patient Dosing In Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical Trial
Brief: Immixbio Ships Tislelizumab For Patient Dosing In Its Combination Clinical Trial With Imx-110 In Advanced Solid Tumors
U.S. STOCKS ON THE MOVE-Pfizer, Harrow Health, Vallon Pharma
U.S. STOCKS ON THE MOVE-Processa Pharma, Solaredge, Immix Biopharma
Immix Biopharma gains on exclusive rights to blood cancer therapy
Brief: Immix Biopharma In-Licenses NXC-201, BCMA-Targeted Next-Generation CAR-T Therapy
Brief: Immix Biopharma Announces Patient Dosing In Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
Brief: ImmixBio Releases, Ships Scaled-Up GMP Batches Of IMX-110 For Clinical Trial
Immix up on pediatric patient enrollment approval in cancer therapy trial